DRY EYE SYNDROME TREATMENT MARKET ANALYSIS

Dry Eye Syndrome Treatment Market, by Product Type (Cyclosporine, Oral Corticosteroid, Artificial Tears, Omega Supplements, Punctual Bags, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Supermarket/ Hypermarket, Other Stores, Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Dec 2022
Code : CMI1173
Pages :187
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Dry Eye Syndrome Treatment Market: Key Developments

In February 2021, Mitotech, SA, a Luxembourg-based single-molecule biotechnology company, in collaboration with Essex Bio-Technology Limited, a bio-pharmaceutical company announce the result of phase 3 clinical study of SkQ1 as a treatment for Dry Eye Disease (DED).The clinical study clearly indicate significant impact of SkQ1on central corneal staining, that is further supported by improvement in visual function to patients suffering from dry eye.

In August 2021, AFT Pharmaceuticals, a specialty pharmaceutical company, provided a clinical study data according to which NovaTears+Omega-3, indicated for dry eye treatment, shows significantly effective treatment for evaporative Dry Eye Disease. The Meibomian Gland Assessment (MGD) score was taken which was improved from an entry level score of 7.1 to 3.0 (p<0.0001) over the course of the study. The latter result supports the hypothesis that the treatment might liquify meibum secretion excreted from the meibomian glands.